Emerging drugs for complicated skin and skin-structure infections

Bibliography

• Stevens DL. Treatments for skin and soft-tissue and surgical site infections due to MDR gram-positive bacteria. J Infect 2009;59(Suppl 1):S32-9
   PubMed Web of Science ®Google Scholar
• Napolitano LM. Early appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Surg Infect (Larchmt) 2008;9(Suppl 1):s17-27
   PubMed Web of Science ®Google Scholar
• Naimi TS, LeDell KH, Como-Sabetti K, Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003;290:2976-84
   PubMed Web of Science ®Google Scholar
• Crum NF, Lee RU, Thornton SA, Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus. Am J Med 2006;119:943-51
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ, Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74
   PubMed Web of Science ®Google Scholar
• EARSS Annual Report 2008. [Accessed 17 May 2010]
   Google Scholar
• Fridkin SK, Hageman JC, Morrison M, Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44
   PubMed Web of Science ®Google Scholar
• Kirby JT, Mutnick AH, Jones RN, Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn Microbiol Infect Dis 2002;43:303-9
   PubMed Web of Science ®Google Scholar
• Wilson MA. Skin and soft-tissue infections: impact of resistant gram-positive bacteria. Am J Surg 2003;186:35S-41S; discussion 2S-3S, 61S-64S
   PubMed Web of Science ®Google Scholar
• Goetghebeur M, Landry PA, Han D, Vicente C. Methicillin-resistant Staphylococcus aureus: a public health issue with economic consequences. Can J Infect Dis Med Microbiol 2007;18:27-34
   PubMed Web of Science ®Google Scholar
• Nathwani D. Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter? J Antimicrob Chemother 2003;51(Suppl 2):ii37-44
   PubMedGoogle Scholar
• Nathwani D. Health economic issues in the treatment of drug-resistant serious gram-positive infections. J Infect 2009;59(Suppl 1):S40-50
   PubMed Web of Science ®Google Scholar
• Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005;189:425-8
   PubMed Web of Science ®Google Scholar
• Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005;26:442-8
   PubMed Web of Science ®Google Scholar
• Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units. Clin Chest Med 1999;20:303-16, viii
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Future gazing in the management of multiply drug-resistant gram-positive infection. J Infect 2009;59(Suppl 1):S75-80
   PubMed Web of Science ®Google Scholar
• Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol 2009;12:476-81
   PubMed Web of Science ®Google Scholar
• Lane WR. Methicillin resistance in staphylococci. Med J Aust 1962;49(1):962-5
   PubMed Web of Science ®Google Scholar
• DeLeo FR, Chambers HF. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 2009;119:2464-74
   PubMed Web of Science ®Google Scholar
• Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza–Louisiana and Georgia, December 2006 – January 2007. MMWR Morb Mortal Wkly Rep 2007;56:325-9
   PubMedGoogle Scholar
• Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2005;41(Suppl 4):S269-72
   PubMed Web of Science ®Google Scholar
• Hussain FM, Boyle-Vavra S, Shete PB, Daum RS. Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J Infect Dis 2002;186:661-7
   PubMed Web of Science ®Google Scholar
• Robert J, Bismuth R, Jarlier V. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J Antimicrob Chemother 2006;57:506-10
   PubMed Web of Science ®Google Scholar
• Staphylococcus aureus resistant to vancomycin–United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-7
   PubMedGoogle Scholar
• Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001;7:327-32
   PubMed Web of Science ®Google Scholar
• Grayson ML. The treatment triangle for staphylococcal infections. N Engl J Med 2006;355:724-7
   PubMed Web of Science ®Google Scholar
• Siberry GK, Tekle T, Carroll K, To decide if clindamycin is optimal drug for MRSA, request a D-Test. AAP Grand Rounds 2004;11:18-9
   Google Scholar
• Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008;46(Suppl 5):S368-77
   PubMed Web of Science ®Google Scholar
• Kuo DC, Chasm RM, Witting MD. Emergency department physician ability to predict methicillin-resistant Staphylococcus aureus skin and soft tissue infections. J Emerg Med 2008
   Web of Science ®Google Scholar
• Bouza E. New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2009;15(Suppl 7):44-52
   PubMed Web of Science ®Google Scholar
• Skhirtladze K, Hutschala D, Fleck T, Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006;50:1372-5
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC, Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98
   PubMedGoogle Scholar
• Burkhardt O, Pletz MW, Mertgen CP, Welte T. Linezolid–the first oxazolidinone in the treatment of nosocomial MRSA pneumonia. Rec Pat Anti Infect Drug Discov 2007;2:123-30
   PubMedGoogle Scholar
• Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 2005;6:2315-26
   PubMed Web of Science ®Google Scholar
• Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004;2:51-9
   PubMedGoogle Scholar
• Tsuji Y, Hiraki Y, Mizoguchi A, Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure. J Infect Chemother 2008;14:156-60
   PubMed Web of Science ®Google Scholar
• Stein GE, Schooley S, Peloquin CA, Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007;60:819-23
   PubMed Web of Science ®Google Scholar
• Norrby R. Linezolid–a review of the first oxazolidinone. Expert Opin Pharmacother 2001;2:293-302
   PubMedGoogle Scholar
• Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis 2002;21:491-8
   PubMed Web of Science ®Google Scholar
• French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003;51(Suppl 2):ii45-53
   PubMedGoogle Scholar
• Yoshida K, Shoji H, Hanaki H, Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid. J Infect Chemother 2009;15:417-9
   PubMed Web of Science ®Google Scholar
• Hill RL, Kearns AM, Nash J, Linezolid-resistant ST36 methicillin-resistant Staphylococcus aureus associated with prolonged linezolid treatment in two paediatric cystic fibrosis patients. J Antimicrob Chemother 2010;65:442-5
   PubMed Web of Science ®Google Scholar
• Wong A, Reddy SP, Smyth DS, Polyphyletic emergence of linezolid-resistant staphylococci in the United States. Antimicrob Agents Chemother 54:742-8
   PubMed Web of Science ®Google Scholar
• Morales G, Picazo JJ, Baos E, Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis 2010;50:821-5
   PubMed Web of Science ®Google Scholar
• Stevens DL, Smith LG, Bruss JB, Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000;44:3408-13
   PubMed Web of Science ®Google Scholar
• Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 2003;4:57-70
   PubMedGoogle Scholar
• Tsuji BT, Rybak MJ. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2005;49:2735-45
   PubMed Web of Science ®Google Scholar
• Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:2538-44
   PubMed Web of Science ®Google Scholar
• Nau R, Eiffert H. Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 2002;15:95-110
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81
   PubMed Web of Science ®Google Scholar
• Kosmidis C, Levine DP. Daptomycin: pharmacology and clinical use. Expert Opin Pharmacother 2010;11:615-25
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM. Microbiology of drugs for treating multiply drug-resistant gram-positive bacteria. J Infect 2009;59(Suppl 1):S17-24
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006;58:1221-9
   PubMed Web of Science ®Google Scholar
• Breedt J, Teras J, Gardovskis J, Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-66
   PubMed Web of Science ®Google Scholar
• Sacchidanand S, Penn RL, Embil JM, Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005;9:251-61
   PubMed Web of Science ®Google Scholar
• Udo EE, Al-Sweih N, Mokaddas E, Antibacterial resistance and their genetic location in MRSA isolated in Kuwait hospitals, 1994-2004. BMC Infect Dis 2006;6:168
   PubMed Web of Science ®Google Scholar
• Bishara J, Pitlik S, Samra Z, Co-trimoxazole-sensitive, methicillin-resistant Staphylococcus aureus, Israel, 1988-1997. Emerg Infect Dis 2003;9:1168-9
   PubMed Web of Science ®Google Scholar
• Chen AE, Goldstein M, Carroll K, Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital. Pediatr Emerg Care 2006;22:717-23
   PubMed Web of Science ®Google Scholar
• Cuevas O, Cercenado E, Goyanes MJ, Staphylococcus spp. in Spain: present situation and evolution of antimicrobial resistance (1986-2006). Enferm Infecc Microbiol Clin 2008;26:269-77
   PubMed Web of Science ®Google Scholar
• Cenizal MJ, Skiest D, Luber S, Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:2628-30
   PubMed Web of Science ®Google Scholar
• Gleckman R, Blagg N, Joubert DW. Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications. Pharmacotherapy 1981;1:14-20
   PubMed Web of Science ®Google Scholar
• Nielsen SL, Black FT. The effect of dicloxacillin and fusidic acid on the extracellular and intracellular killing of Staphylococcus aureus. J Antimicrob Chemother 1998;42:221-6
   PubMed Web of Science ®Google Scholar
• Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999;12(Suppl 2):S45-58
   PubMed Web of Science ®Google Scholar
• Rennie RP. Susceptibility of Staphylococcus aureus to fusidic acid: Canadian data. J Cutan Med Surg 2006;10:277-80
   PubMed Web of Science ®Google Scholar
• Zinn CS, Westh H, Rosdahl VT. An international multicenter study of antimicrobial resistance and typing of hospital Staphylococcus aureus isolates from 21 laboratories in 19 countries or states. Microb Drug Resist 2004;10:160-8
   PubMed Web of Science ®Google Scholar
• Kanellakopoulou K, Tselikos D, Giannitsioti E, Pharmacokinetics of fusidic acid and cefepime in heart tissues: implications for a role in surgical prophylaxis. J Chemother 2008;20:468-71
   PubMed Web of Science ®Google Scholar
• Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents 1999;12(Suppl 2):S59-66
   PubMed Web of Science ®Google Scholar
• Aboltins CA, Page MA, Buising KL, Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007;13:586-91
   PubMed Web of Science ®Google Scholar
• Parras F, Guerrero MC, Bouza E, Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:175-9
   PubMed Web of Science ®Google Scholar
• Christiansen K. Fusidic acid adverse drug reactions. Int J Antimicrob Agents 1999;12(Suppl 2):S3-9
   PubMed Web of Science ®Google Scholar
• Arias CA, Vallejo M, Reyes J, Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase. J Clin Microbiol 2008;46:892-6
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008;60:433-6
   PubMed Web of Science ®Google Scholar
• Gobernado M. Fosfomycin. Rev Esp Quimioter 2003;16:15-40
   PubMedGoogle Scholar
• Nakazawa H, Kikuchi Y, Honda T, Enhancement of antimicrobial effects of various antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) by combination with fosfomycin. J Infect Chemother 2003;9:304-9
   PubMedGoogle Scholar
• Nannini EC, Stryjewski ME. A new lipoglycopeptide: telavancin. Expert Opin Pharmacother 2008;9:2197-207
   PubMed Web of Science ®Google Scholar
• Leonard SN, Rybak MJ. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 2008;28:458-68
   PubMed Web of Science ®Google Scholar
• Stryjewski ME, O'Riordan WD, Lau WK, Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-7
   PubMed Web of Science ®Google Scholar
• Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007;51:3612-6
   PubMed Web of Science ®Google Scholar
• Wannet WJ, Spalburg E, Heck ME, Widespread dissemination in The Netherlands of the epidemic berlin methicillin-resistant Staphylococcus aureus clone with low-level resistance to oxacillin. J Clin Microbiol 2004;42:3077-82
   PubMed Web of Science ®Google Scholar
• Wertheim HF, Vos MC, Boelens HA, Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004;56:321-5
   PubMed Web of Science ®Google Scholar
• Draghi DC, Sheehan DJ, Hogan P, Sahm DF. In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 2005;49:5024-32
   PubMed Web of Science ®Google Scholar
• Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 2008;62:416-26
   PubMed Web of Science ®Google Scholar
• Woodford N, Livermore DM. Infections caused by gram-positive bacteria: a review of the global challenge. J Infect 2009;59(Suppl 1):S4-16
   PubMed Web of Science ®Google Scholar
• Seybold U, Kourbatova EV, Johnson JG, Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 2006;42:647-56
   PubMed Web of Science ®Google Scholar
• Vollmer W, Blanot D, de Pedro MA. Peptidoglycan structure and architecture. FEMS Microbiol Rev 2008;32:149-67
   PubMed Web of Science ®Google Scholar
• Oku Y, Kurokawa K, Matsuo M, Pleiotropic roles of polyglycerolphosphate synthase of lipoteichoic acid in growth of Staphylococcus aureus cells. J Bacteriol 2009;191:141-51
   PubMed Web of Science ®Google Scholar
• Falconer SB, Brown ED. New screens and targets in antibacterial drug discovery. Curr Opin Microbiol 2009;12:497-504
   PubMed Web of Science ®Google Scholar
• D'Elia MA, Millar KE, Bhavsar AP, Probing teichoic acid genetics with bioactive molecules reveals new interactions among diverse processes in bacterial cell wall biogenesis. Chem Biol 2009;16:548-56
   PubMed Web of Science ®Google Scholar
• D'Elia MA, Henderson JA, Beveridge TJ, The N-acetylmannosamine transferase catalyzes the first committed step of teichoic acid assembly in Bacillus subtilis and Staphylococcus aureus. J Bacteriol 2009;191:4030-4
   PubMed Web of Science ®Google Scholar
• Grundling A, Schneewind O. Synthesis of glycerol phosphate lipoteichoic acid in Staphylococcus aureus. Proc Natl Acad Sci USA 2007;104:8478-83
   PubMed Web of Science ®Google Scholar
• Osborne CS, Neckermann G, Fischer E, In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models. Antimicrob Agents Chemother 2009;53:3777-81
   PubMed Web of Science ®Google Scholar
• Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002;418:884-9
   PubMed Web of Science ®Google Scholar
• Fairhead H. SASP gene delivery: a novel antibacterial approach. Drug News Perspect 2009;22:197-203
   PubMed Web of Science ®Google Scholar
• Brinster S, Lamberet G, Staels B, Type II fatty acid synthesis is not a suitable antibiotic target for gram-positive pathogens. Nature 2009;458:83-6
   PubMed Web of Science ®Google Scholar
• Barczak AK, Hung DT. Productive steps toward an antimicrobial targeting virulence. Curr Opin Microbiol 2009;12:490-6
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2005;41:1407-15
   PubMed Web of Science ®Google Scholar
• Schirmer PL, Deresinski SC. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther 2009;7:777-91
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
   PubMed Web of Science ®Google Scholar
• Peppard WJ, Schuenke CD. Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections. Curr Opin Investig Drugs 2008;9:210-25
   PubMed Web of Science ®Google Scholar
• Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Rec Pat Anti Infect Drug Discov 2008;3:10-33
   PubMedGoogle Scholar
• Kohlhoff SA, Sharma R. Iclaprim. Expert Opin Investig Drugs 2007;16:1441-8
   PubMed Web of Science ®Google Scholar
• Allen NE, Nicas TI. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev 2003;26:511-32
   PubMed Web of Science ®Google Scholar
• Poulakou G, Giamarellou H. Oritavancin: a new promising agent in the treatment of infections due to gram-positive pathogens. Expert Opin Investig Drugs 2008;17:225-43
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Ge Y, In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007;60:300-11
   PubMed Web of Science ®Google Scholar
• Parish D, Scheinfeld N. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs 2008;9:201-9
   PubMed Web of Science ®Google Scholar
• Urgently needed: new antibiotics. Lancet 2009;374:1868
   Web of Science ®Google Scholar
• Karlberg JP. Trends in disease focus of drug development. Nat Rev Drug Discov 2008;7:639-40
   PubMed Web of Science ®Google Scholar